Durable Response in NTRK Fusion-Positive Advanced Salivary Gland Tumor: A Case Report.

IF 0.7 Q4 ONCOLOGY
Case Reports in Oncology Pub Date : 2025-05-12 eCollection Date: 2025-01-01 DOI:10.1159/000545744
George A Oblitas Alca, Lizeth Ayala Loma, Lisde González, Pedro Vega, Yashira L Negrón Abril, Daniel Sumarriva
{"title":"Durable Response in <i>NTRK</i> Fusion-Positive Advanced Salivary Gland Tumor: A Case Report.","authors":"George A Oblitas Alca, Lizeth Ayala Loma, Lisde González, Pedro Vega, Yashira L Negrón Abril, Daniel Sumarriva","doi":"10.1159/000545744","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>NTRK</i> fusions lead to the production of constitutively active TRK proteins, which drive oncogenesis in approximately 0.2% of cancers. However, these fusions occur more frequently in salivary gland-type tumors, making them a promising therapeutic target in patients with advanced disease. Recent studies have shown that TRK inhibitors, such as entrectinib, larotrectinib and repotrectinib, are effective in treating solid tumors harboring <i>NTRK</i> gene fusions. This underscores the importance of incorporating comprehensive molecular profiling in these tumors to identify actionable biomarkers and broaden treatment options.</p><p><strong>Case presentation: </strong>Here, we present the clinical journey of a patient diagnosed with unresectable salivary gland carcinoma that was refractory to both local and systemic treatments. Following molecular profiling, NTRK targeted therapy was initiated, resulting in a significant and sustained response.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first reported case in Bolivia of a salivary gland tumor with an <i>NTRK</i> fusion identified through molecular profiling, followed by successful treatment with compassionate use of entrectinib. This case not only demonstrates the therapeutic benefits and safety of NTRK inhibitors but also underscores the importance of personalized therapy guided by molecular profiling in oncology.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"830-835"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180797/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000545744","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: NTRK fusions lead to the production of constitutively active TRK proteins, which drive oncogenesis in approximately 0.2% of cancers. However, these fusions occur more frequently in salivary gland-type tumors, making them a promising therapeutic target in patients with advanced disease. Recent studies have shown that TRK inhibitors, such as entrectinib, larotrectinib and repotrectinib, are effective in treating solid tumors harboring NTRK gene fusions. This underscores the importance of incorporating comprehensive molecular profiling in these tumors to identify actionable biomarkers and broaden treatment options.

Case presentation: Here, we present the clinical journey of a patient diagnosed with unresectable salivary gland carcinoma that was refractory to both local and systemic treatments. Following molecular profiling, NTRK targeted therapy was initiated, resulting in a significant and sustained response.

Conclusion: To our knowledge, this is the first reported case in Bolivia of a salivary gland tumor with an NTRK fusion identified through molecular profiling, followed by successful treatment with compassionate use of entrectinib. This case not only demonstrates the therapeutic benefits and safety of NTRK inhibitors but also underscores the importance of personalized therapy guided by molecular profiling in oncology.

NTRK融合阳性晚期唾液腺肿瘤的持久反应1例报告。
导语:NTRK融合导致组成活性TRK蛋白的产生,在大约0.2%的癌症中驱动肿瘤发生。然而,这些融合更常发生在唾液腺型肿瘤中,使其成为晚期疾病患者的一个有希望的治疗靶点。最近的研究表明,TRK抑制剂如enterrectinib、larorectinib和repotrectinib对含有NTRK基因融合物的实体肿瘤有效。这强调了在这些肿瘤中结合全面的分子分析来识别可操作的生物标志物和拓宽治疗选择的重要性。病例介绍:在这里,我们提出了一个病人的临床历程诊断为不可切除的唾液腺癌,是难治性的局部和全身治疗。根据分子分析,NTRK靶向治疗被启动,导致显著和持续的反应。结论:据我们所知,这是玻利维亚第一例通过分子谱鉴定出的具有NTRK融合的唾液腺肿瘤,随后使用entrectinib成功治疗。该病例不仅证明了NTRK抑制剂的治疗益处和安全性,而且强调了以分子谱分析为指导的个性化治疗在肿瘤学中的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信